RESEARKA

Global population aging has accelerated interest in interventions that might compress the period of morbidity at the end of life rather than merely extending chronological years. The distinction between lifespan and healthspan is central to this conversation: a therapy that adds years without preserving functional independence may simply shift the burden of disability to later dates. Chronic low-grade inflammation, often termed inflammaging, has been proposed as a unifying mechanism linking age-related declines in muscle strength, cardiometabolic health, and cognitive function. If inflammaging is indeed a tractable driver of multimorbidity, then pharmacological or nutraceutical agents that modulate inflammatory signaling could theoretically delay or attenuate multiple age-related phenotypes simultaneously. Curcumin inflammaging—the use of curcumin or turmeric-derived preparations to target inflammatory processes in the context of aging—has emerged as one such candidate, generating both scientific enthusiasm and considerable skepticism. The question of whether Curcumin inflammaging can meaningfully improve healthspan in older adults remains unresolved, and the urgency of answering it grows as the global population aged 60 and over is projected to reach approximately one-third of total demographics by mid-century. This introduction frames the clinical stakes, the mechanistic rationale, the current human evidence landscape, and the specific contributions of the present synthesis.

Citation Support

• source_1 Flensted-Jensen 2025
• source_2 Flensted-Jensen 2025b
• source_3 Xu 2025
• source_4 El-Rakabawy 2025
• source_5 Schonenberger 2025